New drug trial targets Hard-to-Treat thyroid and salivary gland cancers

NCT ID NCT07521670

First seen Apr 19, 2026 · Last updated May 06, 2026 · Updated 2 times

Summary

This study tests a drug called sacituzumab tirumotecan in people whose adenoid cystic carcinoma (a rare salivary gland cancer) or papillary thyroid carcinoma has returned or spread. The goal is to see if the drug can shrink tumors. About 68 participants will receive the drug by IV twice a month. This is an early-phase trial, so the main focus is on safety and whether the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center Hospital

    Tokyo, Japan

  • National Cancer Center Korea

    Gyeonggi-do, South Korea

  • National Cancer Centre Singapore

    Singapore, Singapore

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia

  • Seoul National University Hospital

    Seoul, South Korea

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • University of Malaya Medical Center

    Kuala Lumpur, Malaysia

Conditions

Explore the condition pages connected to this study.